Clinical Trial Update: Combination of Everolimus and Octreotide LAR in Aggressive Recurrent Meningiomas [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of everolimus and octreotide LAR in aggressive recurrent meningiomas has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningioma

Drugs mentioned

• Everolimus (everolimus)
• Octreotide LAR (octreotide long-acting release)

Snippet

Sponsor: Assistance Publique Hopitaux De Marseille | Conditions: Recurrent Meningiomas, Resistant Meningiomas | Phase 2 | Status: COMPLETED